Abstract 598
Background
U.S. Food and Drug Administration (FDA) approves drugs based on overall survival (OS) in oncology trials in order to speed up access of novel drugs to the market.
Methods
We examined all adult anticancer drugs approved by the FDA from Jan’2006 to Jan’2019. Data regarding the approval type (regular or accelerated), cancer type, treatment indication, and basis for approval were extracted from the FDA website and any relevant publications. The basis for approval was categorized into the response rate (RR), progression-free survival (PFS), and overall survival (OS) endpoints and their analysis. Approvals for pediatric cancers, biosimilars, and cancers limited to genetic syndromes were not included in this study.
Results
A total of 258 FDA approvals were analyzed, of which 57 (22.09%) were approved for first-line therapy and 201 (77.91%) for subsequent lines. Sixty-six (25.58%) were approved based on the OS endpoint, 23 (8.91%) in the first line and 43 (16.67%) in the subsequent lines. One hundred ninety-two (74.42%) drugs were granted approval (regular and accelerated) based on surrogate endpoints: 104 (40.31%) of them for RR and 87 (33,72%) for PFS. Thirteen (5.04%) and 91 (35.27%) were approved for RR, and 20 (7.75%) and 67 (25.97%) were approved for PFS in the first and subsequent lines, respectively (Table). Table Out of the total 258 FDA approvals, 66 (25.58%) were accelerated and 192 (74.42%) regular. Ten (3.88%) and 56 (21.71%) obtained accelerated approval in the first and subsequent lines, respectively. Forty-seven (18.22%) and 145 (56.20%) were granted regular approval in the first and subsequent lines, respectively.Table:
486P
Lines of treatment | # of approvals for RR (%) | # of approvals for PFS (%) | # of approvals for OS (%) | Total # of approvals (%) |
---|---|---|---|---|
First line | 13 (5.04) | 20 (7.75) | 23 (8.91) | 57 (22.09) |
Subsequent lines | 91 (35.27) | 67 (25.97) | 43 (16.17) | 201 (77.91) |
Total | 104 (40.31) | 87 (33.72) | 66 (25.58) | 258 (100) |
Conclusions
RR and PFS were the most frequently approved surrogate endpoints, most often for use in later lines of therapy. The accelerated approvals based on surrogate endpoints in later lines of therapy represent a topic of current debate.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5939 - Matrix metalloproteinases and their tissue inhibitors genes abnormal DNA methylation in breast cancer
Presenter: Olga Simonova
Session: Poster Display session 1
Resources:
Abstract
2703 - Uveal melanoma cell lines depend on multiple signaling pathways for survival
Presenter: John Park
Session: Poster Display session 1
Resources:
Abstract
4849 - XAF1 and ZNF313 complex stimulates ER stress-induced apoptosis via direct GRP78 inhibition.
Presenter: Sungchan Jang
Session: Poster Display session 1
Resources:
Abstract
4801 - XAF1 assembles a destructive complex to induce BRCA1-mediated apoptosis via suppressing ERa and switching estrogen function
Presenter: Seung-hun Jang
Session: Poster Display session 1
Resources:
Abstract
3416 - Cancer associated fibroblasts promote cancer progression via Wnt2 secretion in colorectal cancer
Presenter: Hideaki Karasawa
Session: Poster Display session 1
Resources:
Abstract
4273 - Paired-related homeobox 1 overexpression promotes invasion and metastasis and is a prognostic factor for worse disease-free survival in patients with lung cancer
Presenter: Jung-jyh Hung
Session: Poster Display session 1
Resources:
Abstract
4241 - LncRNA-GC1 contributes to gastric cancer chemo-resistance through inhibition of miR-551b-3p and the overexpression of dysbindin
Presenter: Xin Guo
Session: Poster Display session 1
Resources:
Abstract
5388 - GLPG 1790, a new selective EPHA2 inhibitor, is active in colorectal cancer cell lines belonging to the CMS4/mesenchymal-like subtype
Presenter: Pietro Paolo Vitiello
Session: Poster Display session 1
Resources:
Abstract
5208 - Characterisation of growth hormone signal transduction in primary melanoma cell lines
Presenter: Karla Sousa
Session: Poster Display session 1
Resources:
Abstract
3156 - LAPTM5 protein can regulate TGF-β mediated MAPK and Smad signaling pathways in ovarian cancer cell
Presenter: Yan Gao
Session: Poster Display session 1
Resources:
Abstract